Tesofensine Dosing Guide: Oral Protocol, Half-Life & Safety (2026)

Tesofensine is an oral tablet first developed for Parkinson's and Alzheimer's disease. In those early trials, people lost weight without trying. That finding shifted the program toward obesity.

It works in the brain by blocking the reuptake of three signaling chemicals: dopamine, norepinephrine, and serotonin. Blocking reuptake means more of each signal stays active in the gap between brain cells. The practical result studied in trials is lower appetite and a small bump in resting energy use.

This page is a research reference for the doses studied in trials. It is not a treatment plan. It is also not a recommendation to take tesofensine.

The two doses studied most often are 0.25 mg and 0.5 mg, taken as a single oral tablet once a day. A 1.0 mg dose was tested in the original Phase 2 trial but was associated with higher blood pressure and a higher dropout rate. The Phase 3 program in Mexico dropped 1.0 mg and only tested 0.25 mg and 0.5 mg.

In the Astrup 2008 Phase 2 study, patients took the tablet once daily for 24 weeks alongside a calorie-restricted diet. The 0.5 mg arm showed a placebo-subtracted weight loss of about 9.2% (around 9.1 kg). The 0.25 mg arm showed about 6.5%. Placebo lost about 2.0%. This is not a dosing recommendation.

Tesofensine has a half-life of about 9 days. That means a single tablet does not really wear off between doses the way a short-acting drug would. Blood levels build up slowly over the first 4-6 weeks. After that the body reaches steady state, where the amount taken each day matches what is cleared each day.

In practice, trial protocols still asked patients to take the tablet in the morning. The reason is simple: the drug raises norepinephrine and dopamine, which can disrupt sleep. Morning dosing kept the highest signal during the day. This is not a dosing recommendation.

Tesofensine is an oral tablet. There is no reconstitution. The compound is not a peptide in the structural sense — it is a small molecule that survives the stomach and is absorbed after swallowing.

A small number of research suppliers list tesofensine as a powder for laboratory analytical use rather than as a finished tablet. Powder form is not a research-protocol equivalent of the trial tablet. Trial efficacy and safety numbers came from manufactured oral tablets dosed at 0.25 mg or 0.5 mg with known purity, fill, and dissolution. Powder formats do not have those guarantees.

Tesofensine increases the brain levels of three signaling chemicals at the same time: dopamine, norepinephrine, and serotonin. It does this by blocking the transporters that normally pull these chemicals back into the cell after they are released. With less reuptake, more signal stays in the synapse — the small gap between two brain cells.

The drug was first studied for Parkinson's and Alzheimer's disease because dopamine signaling matters in both. The neurological results were weaker than the developer hoped. The unexpected finding was weight loss. Patients lost weight in a dose-dependent way without anyone telling them to diet. That observation moved the program into obesity.

In animal and human studies, two effects show up. The first is reduced appetite, driven by higher dopamine and norepinephrine signaling in the hypothalamus, the part of the brain that helps regulate hunger. The second is a small rise in resting energy use, driven by higher norepinephrine signaling in peripheral tissues. Together these create the calorie gap that pushes weight down.

Half-life is the time it takes for half of a dose to leave the body. For tesofensine that is about 9 days. Most drugs have half-lives measured in hours. A 9-day half-life means each daily tablet adds onto what is still in the body from prior days. Levels keep rising for about 4-6 weeks before they level off.

Two practical effects fall out of this. First, the full appetite effect builds gradually over the first month, not in the first 24 hours. Second, side effects that show up at week 5 or week 6 are not random — they often track steady state, not the most recent tablet.

The Phase 2 and Phase 3 trials enrolled adults with obesity, generally defined as a body mass index of 30-40 kg/m². Patients with significant cardiovascular disease, uncontrolled high blood pressure, and active psychiatric disease were excluded. That matters when reading the safety numbers — the trial population was healthier than the general population that would actually seek the drug.

The most common side effects reported across trials were dry mouth, nausea, dizziness, abdominal pain, constipation, and insomnia. In the original Phase 2 study, about 71% of patients in the 0.5 mg arm completed the 24-week treatment and roughly 20% withdrew due to adverse events. Dry mouth was the single most reported symptom.

This is the most discussed safety topic. In the Phase 2 trial, heart rate rose by an average of 7.4 beats per minute in the 0.5 mg arm versus placebo. Blood pressure did not rise meaningfully at 0.25 mg or 0.5 mg, but it did rise at 1.0 mg. This pattern is why the 1.0 mg dose was dropped from Phase 3 and why US and EU regulators have been reluctant to advance the program without a dedicated cardiovascular outcomes study.

Because tesofensine raises serotonin, dopamine, and norepinephrine, mood and sleep effects are biologically expected. Insomnia is one of the more common reasons people stop. Anxiety, irritability, and mood changes have been reported. In the Phase 2 paper there was no clear depression signal, but a letter to the editor in The Lancet noted that the trial excluded patients with psychiatric histories, which makes the safety estimate look better than it might be in a general population.

Trial efficacy and safety came from manufactured tablets with verified content and uniformity. Research-use product from grey-market suppliers does not carry those guarantees. Variable tablet content is a major source of unexpected adverse events. Verify any certificate of analysis before assuming a research product matches trial dosing.

Because of the 9-day half-life, the appetite-suppression effect builds over the first 4-6 weeks. Some people notice a reduction in cravings within the first week. The full effect typically takes longer.

Tesofensine has more human evidence than most research-use peptide compounds. The two main human data sources are the 2008 Phase 2 Lancet trial led by Astrup and colleagues, and the Mexican Phase 3 program led by Medix in 372 patients.

Tablets are typically stable at room temperature in a closed container away from light, moisture, and heat. Specific shelf-life and storage instructions depend on the supplier and the product formulation. Tablets generally do not need refrigeration the way reconstituted peptides do.

Most issues come from misunderstanding the 9-day half-life. Common confusions, and what the trial record suggests:

Because the half-life is so long, a single missed dose has almost no effect on plasma levels at steady state. In trial protocols, patients were generally instructed to take the next scheduled dose and not double up.

This is one of the most common reasons people stop tesofensine. Trial protocols recommended morning dosing for this reason. Late-day caffeine, late-day stimulants, and late-day blue light can stack with the drug's signal.

A 5-10 bpm rise was expected in the 0.5 mg trial arm. A rise larger than that, especially with chest discomfort or shortness of breath, is a stopping signal. This is one of the strongest reasons clinical use needs blood pressure and heart rate tracking.

Some people notice the appetite effect wears off after several months. The trials did not extend long enough at this dose to fully characterize this. The TIPO-4 extension allowed up-titration to 1.0 mg, but as noted that dose carried more cardiovascular signal.

Anxiety, irritability, or new low mood that started after beginning the drug is a meaningful signal, not a personality issue. Pause and reassess. Combining tesofensine with SSRIs, SNRIs, or MAOIs is specifically discouraged.

Tesofensine is a small molecule taken orally, not an injectable peptide. There is no reconstitution, no BAC water, no insulin syringe math. If you are reading this page after looking for peptide injection technique, you are in the wrong place — try the BPC-157 protocol or semaglutide protocol instead.

As of May 2026, tesofensine is not FDA approved in the United States for any indication. It is not in any active US new drug application pipeline. The FDA's published novel drug approval lists for 2024, 2025, and 2026 do not include tesofensine.

Medix, the Mexican partner of Saniona, ran the 372-patient Phase 3 program. Medix filed a New Drug Application with COFEPRIS (the Mexican equivalent of the FDA) in December 2019. In February 2023, COFEPRIS's technical committee on new molecules issued a favorable opinion, which is not the same as final market authorization. In late 2024, Saniona reported that Medix had not received approval and was in dialogue with the agency. As of May 2026, full Mexican market authorization remains unresolved.

There is no active EU submission. EU regulators, like the FDA, would likely require a dedicated cardiovascular outcomes trial before considering approval. That study has not been conducted.

Tesomet is a combination product: tesofensine plus the beta-blocker metoprolol, designed to counter the heart rate signal. Saniona has been developing Tesomet for hypothalamic obesity and Prader-Willi syndrome. Nupenta is a separate combination product associated with the Mexican program. Neither is FDA approved.

Tesofensine, semaglutide, and tirzepatide all reduce body weight, but they work in completely different ways and have different regulatory profiles. They are not interchangeable.

Tesomet is tesofensine plus metoprolol, a beta-blocker. The reason to add metoprolol is to blunt the heart rate rise that comes with tesofensine. Tesomet is being studied for hypothalamic obesity and Prader-Willi syndrome, not general obesity.

Phentermine is a short-acting stimulant that mostly affects norepinephrine release. Tesofensine is a long-acting reuptake inhibitor affecting three transmitters. Phentermine is FDA approved for short-term obesity use; tesofensine is not approved anywhere in the US.

Other weight-loss and metabolic research compounds covered on Peptide Dosing Protocols:

Tesofensine is usually discussed as a monoamine reuptake inhibitor research compound for appetite and weight loss. Monitoring focuses on cardiovascular context, metabolic trends, and psychiatric or medication-interaction risk.